0.00%
0.87%
0.78%
87.73%
130.73%
160.00%
215.15%
AI Spotlight on CALTX
Company Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease.
It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis.The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Market Data
| Last Price | 208 |
| Change Percentage | 0.87% |
| Open | 206.4 |
| Previous Close | 206.2 |
| Market Cap ( Millions) | 11239 |
| Volume | 45081 |
| Year High | 208.8 |
| Year Low | 80.8 |
| M A 50 | 206.64 |
| M A 200 | 157.74 |
Financial Ratios
| FCF Yield | -2.23% |
| Dividend Yield | 0.00% |
| ROE | -210.18% |
| Debt / Equity | 920.03% |
| Net Debt / EBIDTA | -59.75% |
| Price To Book | 104.57 |
| Price Earnings Ratio | -23.25 |
| Price To FCF | -44.83 |
| Price To sales | 7.02 |
| EV / EBITDA | -32.42 |
News
- Sep -16 - Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
- Sep -06 - Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
- Sep -03 - Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
- Sep -03 - Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
- Aug -14 - 3 Swedish Growth Companies With Up To 30% Insider Ownership
- Aug -13 - Calliditas Interim Report January to June 2024
- Aug -05 - Invitation to the presentation of Calliditas´s interim report January - June 2024
- Aug -01 - Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference
- Jul -31 - Number of shares and votes in Calliditas Therapeutics
- Jul -26 - Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
- Jul -26 - Calliditas’ Phase IIb trial of PBC treatment meets primary endpoint
- Jul -26 - Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
- Jul -04 - Launch of Phase 3 clinical trial with Nefecon in Japan
- Jun -18 - Calliditas provides setanaxib patent update
- Jun -17 - Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
- May -31 - Swedish Growth Companies With High Insider Ownership Spotlight May 2024
- May -30 - Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
- May -29 - Swedish Exchange Highlights: 3 Growth Companies With High Insider Ownership
- May -29 - Swedish Exchange Growth Leaders: 3 Companies With Significant Insider Ownership
- May -28 - Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Therapeutics for Renal Disease Immunoglobulin
Expected Growth : 9.27 %
What the company do ?
Calliditas Therapeutics' Therapeutics for Renal Disease Immunoglobulin is a novel treatment for rare kidney diseases, targeting IgA nephropathy and other autoimmune disorders.
Why we expect these perspectives ?
Strong demand for immunoglobulin therapeutics in renal disease treatment, driven by increasing prevalence of chronic kidney disease and end-stage renal disease. Calliditas Therapeutics' innovative approach and promising clinical trials have positioned the company for significant growth, with a 9.27% growth rate. Additionally, the company's focus on rare diseases and unmet medical needs has created a lucrative market opportunity.
Segment n°2 -> Outlicensing of Product
Expected Growth : 9.27 %
What the company do ?
Outlicensing of a product from Calliditas Therapeutics AB (publ) refers to the process of licensing a pharmaceutical product to another company, allowing them to develop, manufacture, and commercialize it.
Why we expect these perspectives ?
Strong outlicensing demand for Calliditas Therapeutics AB's product, driven by its unique mechanism of action and promising clinical trial results, is fueling growth. Increasing partnerships with pharmaceutical companies seeking to expand their pipeline, coupled with a growing need for innovative treatments, are key drivers of the 9.27% growth rate.
Segment n°3 -> Royalty
Expected Growth : 9.27 %
What the company do ?
Calliditas Therapeutics AB (publ) pays royalties to inventors, researchers, or partners as a percentage of net sales from commercialized products, typically 5-15%.
Why we expect these perspectives ?
The 9.27% growth in royalty from Calliditas Therapeutics AB (publ) is driven by increasing sales of its lead product, Nefecon, for the treatment of primary IgA nephropathy. Strong demand, expanded market reach, and successful commercialization efforts contribute to this growth. Additionally, the company's strategic partnerships and collaborations have enhanced its revenue streams, further fueling the royalty growth.
Calliditas Therapeutics Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| Nefecon | Nefecon is a novel, oral, delayed-release formulation of budesonide, a corticosteroid, for the treatment of patients with IgA nephropathy (IgAN) at risk of rapid disease progression. |
| NEFECON Delayed-Release Capsules | NEFECON Delayed-Release Capsules are a novel, oral, delayed-release formulation of budesonide, a corticosteroid, for the treatment of patients with IgA nephropathy (IgAN) at risk of rapid disease progression. |
Calliditas Therapeutics AB (publ)'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Calliditas Therapeutics AB (publ) is medium, as there are some alternative treatments available for the diseases the company is targeting, but they are not as effective or convenient as the company's products.
Bargaining Power Of Customers
The bargaining power of customers for Calliditas Therapeutics AB (publ) is low, as the company's products are specialized and there are limited alternative options available for patients.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Calliditas Therapeutics AB (publ) is medium, as the company relies on a few key suppliers for raw materials and manufacturing, but has some flexibility to negotiate prices and terms.
Threat Of New Entrants
The threat of new entrants for Calliditas Therapeutics AB (publ) is high, as the biotechnology industry is highly competitive and new companies are constantly emerging with innovative products and technologies.
Intensity Of Rivalry
The intensity of rivalry for Calliditas Therapeutics AB (publ) is high, as the company operates in a highly competitive industry with many established players and new entrants vying for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 73.98% |
| Debt Cost | 7.33% |
| Equity Weight | 26.02% |
| Equity Cost | 10.93% |
| WACC | 8.27% |
| Leverage | 284.36% |
Calliditas Therapeutics AB (publ) : Quality Control
Calliditas Therapeutics AB (publ) passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHM.MC | Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest … |
| LVTX | LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the … |
| PRQR | ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III … |
| NAMS | NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets … |
| CNTA | Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharma Mar
A-Score
1-Year Total Return ->
🥈
Calliditas Therapeutics
A-Score
1-Year Total Return ->
🥉
ProQR Therapeutics
A-Score
1-Year Total Return ->
4
Centessa Pharmaceuticals
A-Score
1-Year Total Return ->
5
LAVA Therapeutics
A-Score
1-Year Total Return ->
6
